The recent publication of the CHOICE-01 study, reporting overall survival (OS) and published in Signal Transduction and Targeted Therapy,¹ recapitulated findings from an earlier publication of the trial.² The CHOICE-01 investigators prospectively randomized patients with locally advanced (IIIB or IIIC) or metastatic non-small-cell lung cancer (NSCLC) without targetable EGFR or ALK mutations to chemotherapy with or without toripalimab, a humanized PD-1 directed IgG4 antibody, and demonstrated an OS improvement associated with toripalimab.

中文翻译：

---

在前瞻性试验中整合新型生物标志物：来自 CHOICE-01 的生物学见解

最近发表的 CHOICE-01 研究报告了总生存期 （OS） 并发表在《信号转导和靶向治疗^》上，1 总结了该试验早期发表的结果。² CHOICE-01 研究人员前瞻性地将无靶向 EGFR 或 ALK 突变的局部晚期（IIIB 或 IIIC）或转移性非小细胞肺癌 （NSCLC） 患者随机分配至联合或不联合特瑞普利单抗（一种人源化 PD-1 定向 IgG4 抗体）化疗组，并证明与特瑞普利单抗相关的 OS 改善。